Impact of TOPAZ-1 eligibility on the survival benefit of durvalumab plus gemcitabine-cisplatin in advanced biliary tract cancer: a multicenter real-world study.

J Gastroenterol · 2026 · PMC13407461 · PMID 41966637

Europe PMC DOI

hedged sentence

0.0690

closest p · 1.4× alpha

0.0690

boldest claim

The sentences

did not reach statistical significancep = 0.069so close (0.05 < p ≤ 0.1)

Among TOPAZ-1-eligible patients, median PFS was 7.9 months (95% CI 6.3–9.6) in the GCD group and 5.4 months (95% CI 4.4–6.4) in the GC group, although this difference did not reach statistical significance (log-rank p = 0.069).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.